Diffuse Midline Glioma H3 K27M-Mutant Overview

Save information for later
Sign Up

Learn About Diffuse Midline Glioma H3 K27M-Mutant

View Main Condition: Brain Tumor

What is the definition of Diffuse Midline Glioma H3 K27M-Mutant?
Diffuse intrinsic pontine glioma (DIPG) is a type of aggressive brain tumor that occurs in the pons, part of the brainstem. The pons is important for many bodily functions, including regulating breathing, heart rate, bladder control, balance, and more.  Diffuse intrinsic pontine glioma primarily affects children, with roughly 150-300 new diagnoses per year. 
What are the causes of Diffuse Midline Glioma H3 K27M-Mutant?
The cause of diffuse intrinsic pontine glioma is not currently known. Research is being done to identify if certain genetic mutations may be causing DIPG. 
What are the symptoms of Diffuse Midline Glioma H3 K27M-Mutant?
Symptoms of diffuse intrinsic pontine glioma often develop quickly. Symptoms may include poor coordination, arm and leg weakness, as well as difficulty controlling eye movements and facial expressions. Some individuals may experience difficulty speaking or eating as well. 
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Diffuse Midline Glioma H3 K27M-Mutant?
The main treatments for diffuse intrinsic pontine glioma currently include radiation therapy and experimental chemotherapy.  Radiation therapy is generally used for newly diagnosed DIPG. Radiation therapy involves the use of high-energy beams, including X-rays or protons, to destroy tumor cells. Various clinical trials have shown that routine chemotherapy is not effective for treating DIPG. Newer treatments combine chemotherapy with biologic therapy that directly target the tumor.  Because of the tumor's location in the brainstem, it is rarely possible to perform surgery without risk of causing neurological damage. 
Who are the top Diffuse Midline Glioma H3 K27M-Mutant Local Doctors?
Mark M. Souweidane
Elite in Diffuse Midline Glioma H3 K27M-Mutant
Dr. Mark M. Souweidane
Neurosurgery | Pediatrics
Elite in Diffuse Midline Glioma H3 K27M-Mutant
Dr. Mark M. Souweidane
Neurosurgery | Pediatrics

Weill Cornell Medicine Brain & Spine Center

1305 York Ave, 9th Floor, 
New York, NY 
212-746-2363
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Mark Souweidane is a Pediatrics specialist and a Neurosurgery provider in New York, New York. Dr. Souweidane is rated as an Elite provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. His top areas of expertise are Diffuse Midline Glioma H3 K27M-Mutant, Brain Tumor, Gliomatosis Cerebri, Craniopharyngioma, and Osteotomy. Dr. Souweidane is currently accepting new patients.

Elite in Diffuse Midline Glioma H3 K27M-Mutant
Dr. Alberto Broniscer
Pediatric Hematology Oncology
Elite in Diffuse Midline Glioma H3 K27M-Mutant
Dr. Alberto Broniscer
Pediatric Hematology Oncology
262 Danny Thomas Place, Ms 0515, St. Jude Children's Research Hospital, 
Memphis, TN 
901-595-3006
Languages Spoken:
English
See accepted insurances

Alberto Broniscer is a Pediatric Hematologist Oncology provider in Memphis, Tennessee. Dr. Broniscer is rated as an Elite provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. His top areas of expertise are Diffuse Midline Glioma H3 K27M-Mutant, Brain Stem Cancer, Glioma, and Medulloblastoma.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Diffuse Midline Glioma H3 K27M-Mutant
Dr. Michelle L. Monje
Pediatric Neurology | Neurology
Elite in Diffuse Midline Glioma H3 K27M-Mutant
Dr. Michelle L. Monje
Pediatric Neurology | Neurology
725 Welch Rd, 
Palo Alto, CA 
650-497-8000
Languages Spoken:
English
See accepted insurances

Michelle Monje is a Pediatric Neurologist and a Neurologist in Palo Alto, California. Dr. Monje is rated as an Elite provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. Her top areas of expertise are Diffuse Midline Glioma H3 K27M-Mutant, Brain Stem Cancer, Glioma, and Gliomatosis Cerebri.

View All Doctors
What is the outlook (prognosis) for Diffuse Midline Glioma H3 K27M-Mutant?
The prognosis for diffuse intrinsic pontine glioma is very poor. Although there is no cure, a small percentage of patients survive.
What are the latest Diffuse Midline Glioma H3 K27M-Mutant Clinical Trials?
PEACH TRIAL- Precision mEdicine and Adoptive Cellular tHerapy for the Treatment of Recurrent Neuroblastoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG)
PEACH TRIAL- Precision mEdicine and Adoptive Cellular tHerapy for the Treatment of Recurrent Neuroblastoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG)
Who is this study for: Patients with Malignant Glioma, Neuroblastoma
Enrollment Status: Recruiting
Publish Date: October 09, 2025
Intervention Type: Biological
Study Drug: Tumor-Specific Ex Vivo Expanded Autologous Lymphocyte Transfer (TTRNA-xALT)
Study Phase: Phase 1

Summary: A Phase I open-label, multicenter study, to evaluate the safety, feasibility, and maximum tolerated dose (MTD) of treating children with newly diagnosed DIPG or recurrent neuroblastoma with molecular targeted therapy in combination with adoptive cell therapy (Total tumor mRNA-pulsed autologous Dendritic Cells (DCs) (TTRNA-DCs), Tumor-specific ex vivo expanded autologous lymphocyte transfer (TTRNA-...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 1/2 Trial of Selinexor (KPT-330) and Radiation Therapy in Newly-Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma (DIPG) and High-Grade Glioma (HGG)
A Phase 1/2 Trial of Selinexor (KPT-330) and Radiation Therapy in Newly-Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma (DIPG) and High-Grade Glioma (HGG)
Who is this study for: Patients with Malignant Glioma, Anaplastic Astrocytoma
Enrollment Status: Recruiting
Publish Date: October 06, 2025
Intervention Type: Drug, Procedure, Radiation
Study Drug: Selinexor
Study Phase: Phase 1/Phase 2

Summary: This phase I/II trial tests the safety, side effects, and best dose of selinexor given in combination with standard radiation therapy in treating children and young adults with newly diagnosed diffuse intrinsic pontine glioma (DIPG) or high-grade glioma (HGG) with a genetic change called H3 K27M mutation. It also tests whether combination of selinexor and standard radiation therapy works to shrink...

View All Clinical Trials
What are some Advocacy Organizations?
keep-punching-brain-cancer

Keep Punching supports patients, healthcare providers, and researchers in their fight to prevent and eradicate brain cancer and minimize treatment-related side effects that may adversely impact function and comfort.